0001624326 false 0001624326 2023-03-31 2023-03-31 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-03-31 2023-03-31 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-03-31 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of Report (Date of earliest event reported): March 31, 2023


(Exact Name of Registrant as Specified in Charter)


Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


360 Madison Avenue, 25th Floor, New York, New York   10017
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (212) 949-4319


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.07. Submission of Matters to a Vote of Security Holders.


On March 31, 2023, PAVmed Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”). Stockholders representing approximately 70.8% of the shares outstanding and entitled to vote were present in person or by proxy. At the Special Meeting, the stockholders approved the sole proposal presented. A description of the proposal considered by the stockholders and a tally of the votes on such proposal are set forth below.


1. A proposal to approve an amendment to the Company’s certificate of incorporation, as amended (the “Certificate of Incorporation”), to effect, at any time prior to the one-year anniversary date of the Special Meeting, (i) a reverse stock split of the Company’s outstanding shares of common stock (the “Reverse Split”) at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the Company’s board of directors (the “Board”) in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue (the “Authorized Capital Reduction”), from 250,000,000 shares to 50,000,000 shares. The amendment to the Certificate of Incorporation was approved, as follows:


For   Against   Abstain   Broker Non-Votes 
 53,080,020    15,037,559    1,009,870     


By approving this amendment, the Company’s stockholders authorized the Company, at any time prior to March 31, 2024, to effect the Reverse Split and Authorized Capital Reduction. However, the Company also reserved the right to abandon the Reverse Split and Authorized Capital Reduction. The Company has not yet determined the specific ratio of the Reverse Split or the timing of the Reverse Split and Authorized Capital Reduction, or whether the Company will effect the Reverse Split and Authorized Capital Reduction at all.


If the Company proceeds with the Reverse Split and Authorized Capital Reduction, the Company will effectuate the amendment to its Certificate of Incorporation by filing a certificate of amendment with the Delaware Secretary of State.


A fuller description of the amendment to the Certificate of Incorporation, including the Reverse Split and the Authorized Capital Reduction, is set forth on pages 5 to 13 the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 21, 2023 (the “Proxy Statement”), which description is incorporated herein by reference. The description of the amendment to the Certificate of Incorporation, including the Reverse Split and the Authorized Capital Reduction, does not purport to be complete and is qualified in its entirety by reference to the full text of the amendment, which is included as Annex A to the Proxy Statement and is incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:


Exhibit No.   Description
3.1   Form of Certificate of Amendment.(1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).


(1) Incorporated by reference to Annex A of the Proxy Statement.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: March 31, 2023 PAVMED INC.
  By: /s/ Dennis McGrath
    Dennis McGrath
    President and Chief Financial Officer




EX-101.SCH 2 pavm-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 pavm-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 4 pavm-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, Par Value $0.001 Per Share Series Z Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pavm-20230331_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Mar. 31, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 31, 2023
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 360 Madison Avenue
Entity Address, Address Line Two 25th Floor, New York, New York
Entity Address, Postal Zip Code 10017
City Area Code (212)
Local Phone Number 949-4319
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, Par Value $0.001 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
Security Exchange Name NASDAQ
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2023-03-31 2023-03-31 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-03-31 2023-03-31 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-03-31 2023-03-31 iso4217:USD shares iso4217:USD shares 0001624326 false 8-K 2023-03-31 PAVMED INC. DE 001-37685 47-1214177 360 Madison Avenue 25th Floor, New York, New York 10017 (212) 949-4319 false false false false Common Stock, Par Value $0.001 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 21 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0548-EntityAddressCityOrTown-Missing] Submission type 8-K should have a non-empty value for EntityAddressCityOrTown in the Required Context. form8-k.htm [dq-0548-EntityAddressStateOrProvince, EntityAddressCountry-Inclusive] In submission type 8-K, at least one of EntityAddressStateOrProvince, EntityAddressCountry should have a value. form8-k.htm form8-k.htm pavm-20230331.xsd pavm-20230331_def.xml pavm-20230331_lab.xml pavm-20230331_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "pavm-20230331_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pavm-20230331_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20230331_pre.xml" ] }, "schema": { "local": [ "pavm-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 2, "memberStandard": 0, "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://pavmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "PAVM_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.001 Per Share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://pavmed.com/20230331", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "nsuri": "http://pavmed.com/20230331", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://pavmed.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-010378-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-010378-xbrl.zip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end